Home Cart 0 Sign in  

[ CAS No. 775304-60-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 775304-60-4
Chemical Structure| 775304-60-4
Structure of 775304-60-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 775304-60-4 ]

Related Doc. of [ 775304-60-4 ]

Alternatived Products of [ 775304-60-4 ]

Product Details of [ 775304-60-4 ]

CAS No. :775304-60-4 MDL No. :MFCD09971792
Formula : C16H11FN2O3 Boiling Point : -
Linear Structure Formula :- InChI Key :LFJJTHGQRVVGGN-UHFFFAOYSA-N
M.W : 298.27 Pubchem ID :11208732
Synonyms :

Calculated chemistry of [ 775304-60-4 ]

Physicochemical Properties

Num. heavy atoms : 22
Num. arom. heavy atoms : 17
Fraction Csp3 : 0.06
Num. rotatable bonds : 4
Num. H-bond acceptors : 6.0
Num. H-bond donors : 0.0
Molar Refractivity : 76.41
TPSA : 65.22 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.69 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.3
Log Po/w (XLOGP3) : 3.42
Log Po/w (WLOGP) : 3.75
Log Po/w (MLOGP) : 3.33
Log Po/w (SILICOS-IT) : 3.71
Consensus Log Po/w : 3.5

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.15
Solubility : 0.021 mg/ml ; 0.0000705 mol/l
Class : Moderately soluble
Log S (Ali) : -4.47
Solubility : 0.0101 mg/ml ; 0.0000339 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -6.25
Solubility : 0.000169 mg/ml ; 0.000000568 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 2.97

Safety of [ 775304-60-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 775304-60-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 775304-60-4 ]
  • Downstream synthetic route of [ 775304-60-4 ]

[ 775304-60-4 ] Synthesis Path-Upstream   1~11

  • 1
  • [ 775304-60-4 ]
  • [ 775304-57-9 ]
YieldReaction ConditionsOperation in experiment
96%
Stage #1: at 100℃; for 2 h; Heating / reflux
Stage #2: With hydrogenchloride In water
To a solution of 3-[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid methyl ester (3.3 g, 111 mmol) in THF (40 mL) was added 1.5M aqueous NaOH (10 mL, 14 mmol). The reaction mixture was refluxed for 2 h at 100° C. The organic solvent was removed and the aqueous solution was diluted with water (50 mL), and then acidified with aqueous HCl. The white precipitate was filtered off and the white cake was washed with cold water and then dried using lyophilizer. The desired acid (3.0 g, 96percent yield) was obtained as a white powder with 98percent purity (LC/UV). Melting point 242° C.; IR υ 3000 (Aromatic C-H), 1710 (CO); 1H-NMR (D6-DMSO) δ 8.31 (1H), 8.18 (2H), 8.08 (1H), 7.88 (2H), 7.51 (2H); 13C-NMR (D6-DMSO) δ 172.71, 167.38, 166.48, 161.25, 135.80, 132.24, 131.79, 131.79, 131.08, 130.91, 129.81, 127.76, 125.48, 117.38, 111.70; 19F-NMR (D6-DMSO) δ 109.7.
96%
Stage #1: With sodium hydroxide; water In tetrahydrofuran at 100℃; for 2 h; Heating / reflux
Stage #2: With hydrogenchloride In water
To a solution of 3-[5-(2-Fluoro-phenyl)-[l,2,4]oxadiazol-3-yl]-benzoic acid methyl ester (3.3g, 11 mmol) in THF (40 mL) was added 1.5M aqueous NaOH (10 mL, 14 mmol). The reaction mixture was refluxed for 2h at 100 °C. The organic solvent was removed and the aqueous solution was diluted with water (50 mL), and then acidified with aqueous HCl. The white precipitate was filtered off and the white cake was washed with cold water and then dried using lyophilizer. The desired acid (3.Og5 96percent yield) was obtained as a white powder with 98percent purity (LC/UV). Melting point 242 °C; IR D 3000 (Aromatic C-H), 1710 (C=O); 1H-NMR (D6-DMSO) δ 8.31 (IH), 8.18 (2H)3 8.08 (IH), 7.88 (2H), 7.51 (2H); 13C- NMR (D6-DMSO) δ 172.71, 167.38, 166.48, 161.25, 135.80, 132.24, 131.79, 131.79, 131.08, 130.91, 129.81, 127.76, 125.48, 117.38, 111.70; 19F-NMR (D6-DMSO) δ 109.7.
96%
Stage #1: With sodium hydroxide; water In tetrahydrofuran at 100℃; for 2 h; Heating / reflux
Stage #2: With hydrogenchloride In water
To a solution of 3-[5-(2-Fluoro-phenyl)-[l ,2,4]oxadiazol-3-yl]-benzoic acid methyl ester (3.3g, 1 1 mmol) in THF (40 mL) was added 1.5M aqueous NaOH (10 mL, 14 mmol). The reaction mixture was refluxed for 2h at 100 0C. The organic solvent was removed and the aqueous solution was diluted with water (50 mL), and then acidified with aqueous HCl. The white precipitate was filtered off and the white cake was washed with cold water and then dried using lyophilizer. The desired acid (3.0g, 96percent yield) was obtained as a white powder with 98percent purity (LC/UV). Melting point 242 0C; IR 3000 (Aromatic C-H),ATI-2289908vl 25 <n="27"/>1710 (C=O); 1H-NMR (D6-DMSO) δ 8.31 (IH), 8.18 (2H), 8.08 (IH), 7.88 (2H), 7.51 (2H); 13C-NMR (D6-DMSO) δ 172.71, 167.38, 166.48, 161.25, 135.80, 132.24, 131.79, 131.79, 131.08, 130.91, 129.81, 127.76, 125.48, 1 17.38, 1 11.70; 19F-NMR (D6-DMSO) δ 109.7.
96%
Stage #1: With sodium hydroxide; water In tetrahydrofuran at 100℃; for 2 h;
Stage #2: With hydrogenchloride In water
To a solution of 3-[5-(2-Fluoro-phenyl)-[l ,2,4]oxadiazol-3-yl]-benzoic acid methyl ester (3.3g, 11 mmol) in THF (40 niL) was added 1.5M aqueous NaOH (10 niL, 14 mmol). The reaction mixture was refluxed for 2h at 100 0C. The organic solvent was removed and the aqueous solution was diluted with water (50 mL), and then acidified with aqueous HCl. The white precipitate was filtered off and the white cake was washed with cold water and then dried using lyophilizer. The desired acid (3.Og, 96percent yield) was obtained as a white powder with 98percent purity (LC/UV). Melting point 242 0C; IR D 3000 (Aromatic C-H), 1710 (C=O); 1H-NMR (D6-DMSO) δ 8.31 (IH), 8.18 (2H), 8.08 (IH), 7.88 (2H), 7.51 (2H); 13C-NMR (D6-DMSO) δ 172.71, 167.38, 166.48, 161.25, 135.80, 132.24, 131.79, 131.79, 131.08, 130.91, 129.81, 127.76, 125.48, 117.38, 111.70; 19F-NMR (D6-DMSO) δ 109.7.
123 mg With water; sodium hydroxide In ethanol at 20℃; for 3 h; General procedure: To a solution of methyl ester 13 (228 mg, 0.76 mmol) in EtOH: H2O (3:2, 10 mL) was added crushed NaOH (91 mg, 2.27 mmol) and the solution was stirred at rt for 3h. The volatiles were evaporated under reduced pressure and the residue obtained was acidified with 1N aqueous HCl (pH ~ 4). This solution was then transferred to a separatory funnel and extracted with EtOAc (3 x 20 mL). The combined organic layers were dried Na2SO4 and concentrated under reduced pressure to afford the title acid 14 (123 mg, 54percent) as a white solid.
3 g With water; sodium hydroxide In tetrahydrofuran at 100℃; for 2 h; A solution of 33 g of methyl 3- [5- (2-fluorophenyl) - [1,2,4-oxadiazol-3-yl] -benzoic acid methyl ester was dissolved in 400 mlOf tetrahydrofuran,To this was added 100 ml of a 1.5 M aqueous solution of sodium hydroxide.The reaction mixture was heated at 100 ° C for 2 hours. The solvent was removed under reduced pressure,The aqueous solution was stirred at 5 ° C for 2 hours.The organic solvent was removed, the aqueous solution was diluted with 50 ml of water,Followed by acidification with hydrochloric acid to pH 1. Filter out a white precipitate, wash the filter cake with cold water,And then dried with a freeze drier.To obtain 3. 0 g of 3- [5- (2_ fluorophenyl) - [1,2,4] oxadiazol-3-yl] benzoic acid. (1H), 8.18 (2H), 08.8 (1H), 7.88 (2H), 7.11 (2H). Show that the sample prepared in Preparation Example 1 was incubated with TO2004091502A2 Example 2 prepared ataluren

Reference: [1] Patent: US2004/204461, 2004, A1, . Location in patent: Page 54
[2] Patent: WO2007/117438, 2007, A2, . Location in patent: Page/Page column 261
[3] Patent: WO2008/45566, 2008, A1, . Location in patent: Page/Page column 25-26
[4] Patent: WO2006/110483, 2006, A1, . Location in patent: Page/Page column 21
[5] Advanced Synthesis and Catalysis, 2017, vol. 359, # 5, p. 772 - 778
[6] Patent: WO2008/30570, 2008, A1, . Location in patent: Page/Page column 20-21
[7] Patent: WO2008/30570, 2008, A1, . Location in patent: Page/Page column 21-23
[8] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 11, p. 2473 - 2476
[9] Patent: CN105461650, 2016, A, . Location in patent: Paragraph 0075; 0082
  • 2
  • [ 1141475-82-2 ]
  • [ 393-52-2 ]
  • [ 775304-60-4 ]
YieldReaction ConditionsOperation in experiment
80% With potassium carbonate In acetone at 20℃; for 24 h; General procedure: 2 mmol of either amidoxime 1 [30] or 2 [26] were dissolved in acetone (200 mL) in a round-bottomed flask; then, K2CO3 (0.35 g; 2.5 mmol) and the corresponding aroyl chloride (2.5 mmol), were added to the reaction mixture and stirred for 24 h at room temperature. The solvent was removed under vacuum and the residue treated with water and refluxed for 30 min 1,2,4-Oxadiazoles products were obtained by filtration and further purified by chromatography.
Reference: [1] European Journal of Medicinal Chemistry, 2015, vol. 101, p. 236 - 244
[2] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 11, p. 2473 - 2476
  • 3
  • [ 775304-80-8 ]
  • [ 775304-60-4 ]
YieldReaction ConditionsOperation in experiment
92% at 5 - 130℃; for 22 h; 44g of 3-(N-2-Fluorobenzoylcarbamimidoyl)-benzoic acid methyl ester in toluene (500 mL) was refluxed for 4h at 130 °C using Dean-Stark apparatus. The reaction mixture was stirred at 5 °C for 18h. The white precipitate was filtered off and the filtrate was concentrated, crystallized again in toluene. The desired oxadiazole (38g, 92percent yield) was obtained as a white solid with 99percent purity (LC/UV). 1H-NMR (CDCl3) S 8.91 (IH)5 8.38 (IH)3 8.15 (2H), 7.62 (2H)3 7.35 (2H)3 3.95 (3H).
92% at 5 - 130℃; for 22 h; Dean-Stark apparatus 44g of 3-(N-2-Fluorobenzoylcarbamimidoyl)-benzoic acid methyl ester in toluene (500 mL) was refluxed for 4h at 130 0C using Dean-Stark apparatus. The reaction mixture was stirred at 5 0C for 18h. The white precipitate was filtered off and the filtrate was EPO <DP n="22"/>concentrated, crystallized again in toluene. The desired oxadiazole (38g, 92percent yield) was obtained as a white solid with 99percent purity (LC/UV). 1H-NMR (CDCl3) δ 8.91 (IH), 8.38 (IH), 8.15 (2H), 7.62 (2H)3 7.35 (2H), 3.95 (3H).
Reference: [1] Patent: WO2007/117438, 2007, A2, . Location in patent: Page/Page column 261
[2] Patent: WO2006/110483, 2006, A1, . Location in patent: Page/Page column 20-21
  • 4
  • [ 912461-75-7 ]
  • [ 775304-60-4 ]
YieldReaction ConditionsOperation in experiment
92% at 5 - 130℃; for 22 h; Heating / reflux 44g of 3-(N-2-Fluorobenzoylcarbamimidoyl)-benzoic acid methyl ester in toluene (500 mL) was refluxed for 4h at 130 0C using Dean-Stark apparatus. The reaction mixture was stirred at 5 0C for 18h. The white precipitate was filtered off and the filtrate was concentrated, crystallized again in toluene. The desired oxadiazole (38g, 92percent yield) was obtained as a white solid with 99percent purity (LC/UV). 1H-NMR (CDCl3) δ 8.91 (IH), 8.38 (IH), 8.15 (2H), 7.62 (2H), 7.35 (2H), 3.95 (3H).
38 g at 5 - 130℃; for 22 h; Dean-Stark At 130 ° C with Dean-StarkThe solution was heated to dissolve 44 grams of toluene in 500 ml3- (N-2-fluorobenzoylamidino) -benzoic acid methyl ester for 4 hours.The reaction mixture was stirred at 5 ° C for 18 hours. The white precipitate was filtered off, the filtrate was concentrated,And then crystallized in toluene.To obtain 38 g of methyl 3- [5- (2-fluorophenyl) - [1,2,4-oxadiazol-3-yl] -benzoic acid methyl ester.
Reference: [1] Patent: WO2008/45566, 2008, A1, . Location in patent: Page/Page column 25
[2] Patent: CN105461650, 2016, A, . Location in patent: Paragraph 0075; 0081
  • 5
  • [ 348-52-7 ]
  • [ 775304-60-4 ]
Reference: [1] Advanced Synthesis and Catalysis, 2017, vol. 359, # 5, p. 772 - 778
  • 6
  • [ 394-47-8 ]
  • [ 775304-60-4 ]
Reference: [1] Advanced Synthesis and Catalysis, 2017, vol. 359, # 10, p. 1708 - 1716
  • 7
  • [ 13531-48-1 ]
  • [ 775304-60-4 ]
Reference: [1] Patent: CN105461650, 2016, A,
[2] Advanced Synthesis and Catalysis, 2017, vol. 359, # 5, p. 772 - 778
[3] Patent: WO2006/110483, 2006, A1,
  • 8
  • [ 1141475-82-2 ]
  • [ 775304-60-4 ]
Reference: [1] Advanced Synthesis and Catalysis, 2017, vol. 359, # 5, p. 772 - 778
[2] Patent: WO2006/110483, 2006, A1,
  • 9
  • [ 1877-72-1 ]
  • [ 775304-60-4 ]
Reference: [1] Patent: CN105461650, 2016, A,
  • 10
  • [ 15676-11-6 ]
  • [ 775304-60-4 ]
Reference: [1] Patent: CN105461650, 2016, A,
  • 11
  • [ 1129-28-8 ]
  • [ 775304-60-4 ]
Reference: [1] Advanced Synthesis and Catalysis, 2017, vol. 359, # 10, p. 1708 - 1716
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 775304-60-4 ]

Fluorinated Building Blocks

Chemical Structure| 1092400-82-2

[ 1092400-82-2 ]

3-(5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoic acid

Similarity: 0.72

Chemical Structure| 340736-76-7

[ 340736-76-7 ]

4-(5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoic acid

Similarity: 0.72

Chemical Structure| 1146699-64-0

[ 1146699-64-0 ]

3-(4-(Bromomethyl)-3-fluorophenyl)-1,2,4-oxadiazole

Similarity: 0.64

Chemical Structure| 96187-53-0

[ 96187-53-0 ]

6-Fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid

Similarity: 0.56

Chemical Structure| 96201-88-6

[ 96201-88-6 ]

Sodium 6-fluoro-2-(2'-fluoro-[1,1'-biphenyl]-4-yl)-3-methylquinoline-4-carboxylate

Similarity: 0.56

Aryls

Chemical Structure| 1092400-82-2

[ 1092400-82-2 ]

3-(5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoic acid

Similarity: 0.72

Chemical Structure| 340736-76-7

[ 340736-76-7 ]

4-(5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoic acid

Similarity: 0.72

Chemical Structure| 1146699-64-0

[ 1146699-64-0 ]

3-(4-(Bromomethyl)-3-fluorophenyl)-1,2,4-oxadiazole

Similarity: 0.64

Chemical Structure| 256956-42-0

[ 256956-42-0 ]

3-(4-(Bromomethyl)phenyl)-5-methyl-1,2,4-oxadiazole

Similarity: 0.61

Chemical Structure| 1373156-28-5

[ 1373156-28-5 ]

3-(4-(2-(3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl)-2-(4-methoxyphenyl)ethyl)phenyl)isoxazole-5-carboxylic acid

Similarity: 0.59

Esters

Chemical Structure| 85386-14-7

[ 85386-14-7 ]

Ethyl 2-phenylpyrimidine-5-carboxylate

Similarity: 0.53

Chemical Structure| 148516-11-4

[ 148516-11-4 ]

Ethyl 2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxylate

Similarity: 0.53

Chemical Structure| 952285-52-8

[ 952285-52-8 ]

Methyl 4-amino-2,5-difluorobenzoate

Similarity: 0.52

Chemical Structure| 125568-73-2

[ 125568-73-2 ]

Methyl 5-amino-2,4-difluorobenzoate

Similarity: 0.52

Chemical Structure| 1172889-96-1

[ 1172889-96-1 ]

Methyl 4-carbamimidoylbenzoate acetate

Similarity: 0.51

Related Parent Nucleus of
[ 775304-60-4 ]

Oxadiazoles

Chemical Structure| 1092400-82-2

[ 1092400-82-2 ]

3-(5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoic acid

Similarity: 0.72

Chemical Structure| 340736-76-7

[ 340736-76-7 ]

4-(5-(Trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzoic acid

Similarity: 0.72

Chemical Structure| 1146699-64-0

[ 1146699-64-0 ]

3-(4-(Bromomethyl)-3-fluorophenyl)-1,2,4-oxadiazole

Similarity: 0.64

Chemical Structure| 256956-42-0

[ 256956-42-0 ]

3-(4-(Bromomethyl)phenyl)-5-methyl-1,2,4-oxadiazole

Similarity: 0.61

Chemical Structure| 1373156-28-5

[ 1373156-28-5 ]

3-(4-(2-(3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl)-2-(4-methoxyphenyl)ethyl)phenyl)isoxazole-5-carboxylic acid

Similarity: 0.59